Amplification of the ERBB2 gene on chromosome 17q12 [10] leads to HER2 overexpression in 15%–25% of breast cancers, driving aggressive tumor behavior and poor clinical outcomes [11]. This evidence concerns the gene ERBB2 and breast carcinoma.